» Articles » PMID: 35812606

Sex Differences in COVID-19 Outcomes

Overview
Journal Cureus
Date 2022 Jul 11
PMID 35812606
Authors
Affiliations
Soon will be listed here.
Abstract

Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as the cause of an outbreak of severe acute respiratory syndrome in Wuhan City, China in December 2019. Since then, it has caused a worldwide pandemic with over six million deaths. Many studies have been published on coronavirus disease 2019 (COVID-19), but only a few have compared the outcomes of COVID-19 between males and females, especially in African countries and the Middle East. Studies published to date on this topic report that male patients infected with SARS-CoV-2 have worse outcomes than females. This study aimed to compare sex differences in COVID-19 outcomes in a tertiary care hospital in Casablanca (Morocco). Methodology We included all adult patients hospitalized for COVID-19 infection in Cheikh Khalifa Hospital. We categorized patients according to gender and analyzed the characteristics and outcomes of each group. Results In total, 134 patients with polymerase chain reaction (PCR)-confirmed COVID-19 were admitted during the study period. These included 72 (53.7%) men and 62 (46.4%) women. The median age of the patients was 53 years (interquartile range, IQR = 36-64). Men were significantly older than women (58 vs. 44) but there was no significant difference in comorbidities on comparing men and women. Values of median C-reactive protein (35 vs. 4), ferritin (326 vs. 72), and lactate dehydrogenase (264 vs. 208) were significantly higher in men. Lymphopenia was significantly more important in men (1.2 vs. 1.7), and the ratio of neutrophil/lymphocytes was significantly higher in men (3.37 vs. 1.84). Men had greater disease severity, with significantly higher intensive care unit admission (48.6% vs. 16.1%) and higher hospital mortality (18.1% vs. 1.6%). Conclusions COVID-19 gender disparities may be due to sex differences in the inflammatory response. These can be explained by the role of sex hormones and sex chromosomes on immune cells and their regulatory genes.

Citing Articles

Estrogen-dependent gene regulation: Molecular basis of TIMP-1 as a sex-specific biomarker for acute lung injury.

Almuntashiri S, Dutta S, Zhu Y, Gamare S, Ramirez G, Irineo-Moreno V Physiol Rep. 2024; 12(17):e70047.

PMID: 39267201 PMC: 11392656. DOI: 10.14814/phy2.70047.


Safety of Janssen Ad26.COV.S and Astra Zeneca AZD1222 COVID-19 Vaccines among Mobile Phone Users in Malawi: Findings from a National Mobile-Based Syndromic Surveillance Survey, July 2021 to December 2021.

Makonokaya L, Kapanda L, Woelk G, Chauma-Mwale A, Kalitera L, Nkhoma H Int J Environ Res Public Health. 2023; 20(23).

PMID: 38063553 PMC: 10706488. DOI: 10.3390/ijerph20237123.


Regulation of vascular angiotensin II type 1 and type 2 receptor and angiotensin-(1-7)/MasR signaling in normal and hypertensive pregnancy.

Clark C, Khalil R Biochem Pharmacol. 2023; 220:115963.

PMID: 38061417 PMC: 10860599. DOI: 10.1016/j.bcp.2023.115963.


Gender-based research underscores sex differences in biological processes, clinical disorders and pharmacological interventions.

Bernstein S, Kelleher C, Khalil R Biochem Pharmacol. 2023; 215:115737.

PMID: 37549793 PMC: 10587961. DOI: 10.1016/j.bcp.2023.115737.


COVID-19 is associated with bystander polyclonal autoreactive B cell activation as reflected by a broad autoantibody production, but none is linked to disease severity.

Jiang W, Johnson D, Adekunle R, Heather H, Xu W, Cong X J Med Virol. 2022; 95(1):e28134.

PMID: 36086941 PMC: 9538121. DOI: 10.1002/jmv.28134.

References
1.
Bienvenu L, Noonan J, Wang X, Peter K . Higher mortality of COVID-19 in males: sex differences in immune response and cardiovascular comorbidities. Cardiovasc Res. 2020; 116(14):2197-2206. PMC: 7665363. DOI: 10.1093/cvr/cvaa284. View

2.
Vahidy F, Pan A, Ahnstedt H, Munshi Y, Choi H, Tiruneh Y . Sex differences in susceptibility, severity, and outcomes of coronavirus disease 2019: Cross-sectional analysis from a diverse US metropolitan area. PLoS One. 2021; 16(1):e0245556. PMC: 7806140. DOI: 10.1371/journal.pone.0245556. View

3.
Guan W, Ni Z, Hu Y, Liang W, Ou C, He J . Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18):1708-1720. PMC: 7092819. DOI: 10.1056/NEJMoa2002032. View

4.
El Aidaoui K, Haoudar A, Khalis M, Kantri A, Ziati J, El Ghanmi A . Predictors of Severity in Covid-19 Patients in Casablanca, Morocco. Cureus. 2020; 12(9):e10716. PMC: 7532862. DOI: 10.7759/cureus.10716. View

5.
Zhang H, Penninger J, Li Y, Zhong N, Slutsky A . Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020; 46(4):586-590. PMC: 7079879. DOI: 10.1007/s00134-020-05985-9. View